Merck sells eye business
First Merck sold its consumer business to Bayer. Now, it's also (almost) getting out of the eye-care business. The company announced Tuesday that it has sold part of the business to Santen Pharmaceutical.
The $600-million-plus-milestones deal includes rights to the eye products Cosop, Trusop and Timoptic in Japan and “key markets in Europe and Asia Pacific.” Merck said the sales for these products in these territories is around $400 million a year.
Merck will continue to sell these products in Latin America, Canada and Australia, but sold US rights to Akorn in 2013 and 2014.